JP2009532452A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532452A5 JP2009532452A5 JP2009503667A JP2009503667A JP2009532452A5 JP 2009532452 A5 JP2009532452 A5 JP 2009532452A5 JP 2009503667 A JP2009503667 A JP 2009503667A JP 2009503667 A JP2009503667 A JP 2009503667A JP 2009532452 A5 JP2009532452 A5 JP 2009532452A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- membered
- tautomer
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 43
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- -1 octahydroindolidinyl Chemical group 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229920006395 saturated elastomer Polymers 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- 206010038997 Retroviral infections Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000005959 diazepanyl group Chemical group 0.000 claims 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 claims 1
- 125000005961 oxazepanyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0606663A GB0606663D0 (en) | 2006-04-03 | 2006-04-03 | Therapeutic compounds |
| GB0615907A GB0615907D0 (en) | 2006-08-11 | 2006-08-11 | Therapeutic Compounds |
| GBGB0700432.8A GB0700432D0 (en) | 2007-01-10 | 2007-01-10 | Therapeutic compounds |
| PCT/GB2007/050177 WO2007113596A1 (en) | 2006-04-03 | 2007-04-02 | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009532452A JP2009532452A (ja) | 2009-09-10 |
| JP2009532452A5 true JP2009532452A5 (enExample) | 2010-08-12 |
| JP4611441B2 JP4611441B2 (ja) | 2011-01-12 |
Family
ID=38441875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503667A Active JP4611441B2 (ja) | 2006-04-03 | 2007-04-02 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20090275619A1 (enExample) |
| EP (1) | EP2007733B1 (enExample) |
| JP (1) | JP4611441B2 (enExample) |
| AU (1) | AU2007232297B2 (enExample) |
| CA (1) | CA2647545C (enExample) |
| WO (1) | WO2007113596A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| EA016079B1 (ru) * | 2007-01-10 | 2012-01-30 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа | Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp) |
| AR066721A1 (es) * | 2007-05-24 | 2009-09-09 | Wyeth Corp | Derivados de benzo[d]imidazol-1-il, composicion farmaceutica, proceso de preparacion y uso. |
| JP2011503111A (ja) * | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
| NZ586675A (en) * | 2008-01-08 | 2012-04-27 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| WO2009099736A2 (en) * | 2008-02-06 | 2009-08-13 | Lead Therapeutics, Inc. | Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp) |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| ITFI20090005A1 (it) * | 2009-01-19 | 2010-07-20 | Alberto Chiarugi | Formulazioni farmaceutiche per indurre immunosoppressione attraverso l'inibizione del fenomeno dell'epitope spreading e loro uso. |
| JP5852958B2 (ja) * | 2009-07-14 | 2016-02-03 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｐａｒｐ阻害剤としての３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−カルボキサミド |
| WO2011006803A1 (en) * | 2009-07-14 | 2011-01-20 | Nerviano Medical Sciences S.R.L. | 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition |
| WO2011123795A1 (en) | 2010-04-02 | 2011-10-06 | Battelle Memorial Institute | Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies |
| EP2569307A2 (en) | 2010-05-10 | 2013-03-20 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
| WO2012006958A1 (en) * | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | Amids substituted indazole derivativees as ploy(adp-ribose)polymerase inhibitors |
| CN103052633B (zh) * | 2010-07-14 | 2016-03-23 | 贝达药业股份有限公司 | 酰胺基取代的吲唑衍生物类聚(adp-核糖)聚合酶抑制剂 |
| EP2642998B1 (en) | 2010-11-24 | 2020-09-16 | The Trustees of Columbia University in the City of New York | A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease |
| JP5902299B2 (ja) * | 2011-07-26 | 2016-04-13 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｐａｒｐ−１阻害剤としての３−オキソ−２，３−ジヒドロ−１ｈ−インダゾール−４−カルボキサミド誘導体 |
| WO2013049062A2 (en) | 2011-09-26 | 2013-04-04 | Nitto Denko Corporation | Highly-fluorescent and photo-stable chromophores for enhanced solar harvesting efficiency |
| WO2013052381A2 (en) | 2011-10-05 | 2013-04-11 | Nitto Denko Corporation | Wavelength conversion film having pressure sensitive adhesive layer to enhance solar harvesting efficiency |
| TW201331192A (zh) * | 2012-01-17 | 2013-08-01 | Zhejiang Beta Pharma Inc | 醯胺基取代的吲唑衍生物類聚（ａｄｐ－核糖）聚合酶抑制劑 |
| WO2013166037A1 (en) | 2012-05-01 | 2013-11-07 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of eye disorders |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| ES2700541T3 (es) | 2013-03-14 | 2019-02-18 | Univ Columbia | Octahidrociclopentapirroles, su preparación y uso |
| US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| WO2014151936A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles, their preparation and use |
| WO2014152013A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | 4-phenylpiperidines, their preparation and use |
| EP3483167A1 (en) | 2013-06-26 | 2019-05-15 | AbbVie Inc. | Primary carboxamides as btk inhibitors |
| US10989719B2 (en) * | 2013-10-11 | 2021-04-27 | National University Corporation Tokyo Medical And Dental University | Methods for treating spinocerebellar ataxia type I using RPA1 |
| DK4036094T3 (da) | 2014-04-30 | 2026-03-23 | Univ Columbia | Erstattede 4-fenylpiperidiner, deres fremstilling og anvendelse |
| JP6878316B2 (ja) * | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| ES2879434T3 (es) | 2015-07-23 | 2021-11-22 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| EP3411373A1 (en) | 2016-02-05 | 2018-12-12 | Syngenta Participations AG | Pesticidally active heterocyclic derivatives with sulphur containing substituents |
| FI3478286T3 (fi) | 2016-06-29 | 2024-03-14 | Tesaro Inc | Menetelmiä munasarjasyövän hoitamiseksi |
| CN119606965A (zh) | 2016-07-29 | 2025-03-14 | 詹森药业有限公司 | 治疗前列腺癌的方法 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EA201992177A1 (ru) | 2017-03-27 | 2020-02-25 | Тесаро, Инк. | Композиции на основе нирапариба |
| WO2018187187A1 (en) | 2017-04-04 | 2018-10-11 | Combiphos Catalysts, Inc. | Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide |
| CN110753684A (zh) | 2017-04-24 | 2020-02-04 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR102014478B1 (ko) * | 2017-05-12 | 2019-08-26 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| WO2018208123A1 (ko) * | 2017-05-12 | 2018-11-15 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| EP3624850A1 (en) | 2017-05-18 | 2020-03-25 | Tesaro, Inc. | Combination therapies for treating cancer |
| EP3668857B1 (en) | 2017-08-14 | 2023-07-05 | Teva Pharmaceuticals International GmbH | Processes for the preparation of niraparib and intermediates thereof |
| AU2018341479B2 (en) | 2017-09-26 | 2022-02-17 | Tesaro, Inc. | Niraparib formulations |
| KR20200086664A (ko) | 2017-09-30 | 2020-07-17 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| MA50618A (fr) | 2017-10-06 | 2020-08-12 | Tesaro Inc | Polyrhérapies et leurs utilisations |
| EP3749352A1 (en) | 2018-02-05 | 2020-12-16 | Tesaro Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| SG11202008536QA (en) | 2018-03-29 | 2020-10-29 | Elex Biotech Inc | Compounds for treatment of cardiac arrhythmias and heart failure |
| US20210030680A1 (en) * | 2018-04-13 | 2021-02-04 | The Board Of Regents Of University Of Texas System | Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer |
| US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| KR102735378B1 (ko) * | 2018-11-09 | 2024-11-27 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| WO2020263967A1 (en) * | 2019-06-27 | 2020-12-30 | Biogen Ma Inc. | 2h-indazole derivatives and their use in the treatment of disease |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CA3169303A1 (en) * | 2020-02-24 | 2021-09-02 | Xiaokun SHEN | Application of poly adp-ribose polymerase inhibitors in corona virus resistance |
| CN121398822A (zh) | 2023-06-21 | 2026-01-23 | 四方生物科学有限公司 | 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT841924E (pt) * | 1995-08-02 | 2003-02-28 | Univ Newcastle Ventures Ltd | Compostos de benzimidazolo |
| EP1391457B1 (de) * | 1998-11-03 | 2013-12-25 | AbbVie Deutschland GmbH & Co KG | Substituierte 2-Phenylbenzimidazole und deren Verwendung als PARP Inhibitoren |
| AU755694B2 (en) * | 1998-11-17 | 2002-12-19 | Basf Aktiengesellschaft | 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| USRE39608E1 (en) * | 1998-11-27 | 2007-05-01 | Abbott Gmbh & Co. Kg | Substituted benzimidazoles and their use as PARP inhibitors |
| DE19918211A1 (de) * | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| US7041675B2 (en) * | 2000-02-01 | 2006-05-09 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as PARP inhibitors |
| DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| JP2003005323A (ja) * | 2001-06-20 | 2003-01-08 | Konica Corp | 熱現像写真感光材料及び画像形成方法 |
| CA2509202A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
| US7544707B2 (en) * | 2003-12-22 | 2009-06-09 | Eli Lilly And Company | Bicyclic derivatives as PPAR modulators |
| PL1794163T3 (pl) * | 2004-09-22 | 2010-06-30 | Pfizer | Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| WO2006110683A1 (en) * | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
| CA2623822C (en) * | 2005-09-29 | 2013-11-12 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
| WO2007059230A2 (en) * | 2005-11-15 | 2007-05-24 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| US20070259937A1 (en) * | 2006-05-02 | 2007-11-08 | Giranda Vincent L | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| EA016079B1 (ru) * | 2007-01-10 | 2012-01-30 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа | Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp) |
-
2007
- 2007-04-02 US US12/225,857 patent/US20090275619A1/en not_active Abandoned
- 2007-04-02 WO PCT/GB2007/050177 patent/WO2007113596A1/en not_active Ceased
- 2007-04-02 AU AU2007232297A patent/AU2007232297B2/en active Active
- 2007-04-02 JP JP2009503667A patent/JP4611441B2/ja active Active
- 2007-04-02 EP EP07733600.6A patent/EP2007733B1/en active Active
- 2007-04-02 CA CA2647545A patent/CA2647545C/en active Active
-
2011
- 2011-04-21 US US13/091,427 patent/US20110201657A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021202962C1 (en) | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | |
| EP4139286B1 (en) | Substituted aminothiazoles as dgkzeta inhibitors for immune activation | |
| AU2014364744B2 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
| EP2775841B1 (en) | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| JP2010536842A5 (enExample) | ||
| ES2967119T3 (es) | Compuestos inhibidores de metaloenzimas | |
| US11591311B2 (en) | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides | |
| AU2009260726B2 (en) | S1P1 receptor agonists and use thereof | |
| DK2694510T3 (en) | IMIDAZOPYRIDAZINER AS AKT kinase inhibitors | |
| ES2934227T3 (es) | Inhibidores de isoindolinona de la interacción mdm2-p53 con actividad anticancerígena | |
| JP2011513475A5 (enExample) | ||
| JP2009538897A5 (enExample) | ||
| JP2013544261A5 (enExample) | ||
| AU2016322848B2 (en) | 1-phenylpyrrolidin-2-one derivatives as perk inhibitors | |
| EP3013815B1 (en) | Carbazole carboxamide compounds useful as kinase inhibitors | |
| CA3082856A1 (en) | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides | |
| EP2922847A1 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase | |
| EP3870296A1 (en) | 5-membered heteroaryl carboxamide compounds for treatment of hbv | |
| IL272098B2 (en) | Dihydrooxadiazinones | |
| US20240124422A1 (en) | Mutant pi3k-alpha inhibitors and their use as pharmaceuticals | |
| EP3209664A1 (en) | Bicyclic heteroaryl amine compounds as pi3k inhibitors | |
| WO2016064958A1 (en) | Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors | |
| JP2013501785A (ja) | 結核阻害剤としてのピリミジン化合物 | |
| IL297305A (en) | The heteroaryl carboxamide compounds of pentadentate compounds for the treatment of HBV | |
| CA3079081A1 (en) | Benzimidazole derivatives and their uses |